Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Contrary to opioids, which bind to µ-opioid receptors from the central nervous method, conolidine modulates alternate molecular targets. A Science Innovations review discovered that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which